Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-04

AUTHORS

Osman Köstek, Erdem Yılmaz, Muhammet Bekir Hacıoğlu, Nazım Can Demircan, Ali Gökyer, Sernaz Uzunoğlu, Nermin Tunçbilek, İrfan Çiçin, Bülent Erdoğan

ABSTRACT

PURPOSE: To evaluate whether sunitinib and pazopanib treatments are associated with change in skeletal muscle area (SMA) and total lean body mass (LBM) as well as to compare their efficacies and safety profiles in patients with metastatic renal cell cancer (mRCC). METHODS: Thirty-six patients treated with a tyrosine kinase inhibitor were included. Eighteen of them received sunitinib and the rest/remaining received pazopanib in the first line of mRCC treatment. Baseline and follow-up computed tomography studies of the patients were performed to measure cross-sectional areas (cm2) of muscle tissues. RESULTS: About 69% of patients were male and median age was 60 (49-68) years. Median time interval between two CT imagings was 6.1 (3.1-7.7) months and it was similar between the two groups (for sunitinib, 4.9 (2.5-6.9) months vs for pazopanib, 7.3 (3.2-9.5) months, p = 0.16, respectively). Disease control rate was 77.7% in all patients. Of these, 66.6% in sunitinib group was consisted of four partial responses and eight stable diseases. In addition, 88.8% in pazopanib group was consisted of three partial responses and 13 stable diseases. A significant decrease in SMA and LBM was observed after sunitinib therapy, whereas SMA and LBM values of pazopanib group did not change significantly (p = 0.02 and p = 0.70, respectively). No significant differences were observed between patients with sunitinib, and pazopanib group median PFS [11.9 (95% CI 6.1-17.6) vs 8.1 months (95% CI 7.2-9.1), respectively; p = 0.28] and median OS [28.6 (95% CI 24.3-32.9) vs 25.5 months (95% CI 18.9-52.7), respectively; p = 0.42]. Dose-limiting toxicities were significantly more frequent in sunitinib group than in pazopanib group (66.7% vs 22.2%, p = 0.02, respectively). CONCLUSIONS: Loss of SMA and LBM with sunitinib was more substantial than with pazopanib. Treatment efficacies of both drugs were similar, but dose-limiting toxicity was more frequent in sunitinib group. Loss of SMA had no significant association with prognosis. Further studies are needed to clarify the possible association between SMA and prognosis in mRCC patients who receive sunitinib or pazopanib. More... »

PAGES

735-742

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-019-03779-5

DOI

http://dx.doi.org/10.1007/s00280-019-03779-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1111653380

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30680522


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Trakya University", 
          "id": "https://www.grid.ac/institutes/grid.411693.8", 
          "name": [
            "Division of Medical Oncology, Department of Internal Medicine, Trakya University School of Medicine, 22030, Edirne, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "K\u00f6stek", 
        "givenName": "Osman", 
        "id": "sg:person.01152402121.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01152402121.64"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Trakya University", 
          "id": "https://www.grid.ac/institutes/grid.411693.8", 
          "name": [
            "Department of Radiology, Trakya University School of Medicine, Edirne, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Y\u0131lmaz", 
        "givenName": "Erdem", 
        "id": "sg:person.01247047601.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01247047601.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Trakya University", 
          "id": "https://www.grid.ac/institutes/grid.411693.8", 
          "name": [
            "Division of Medical Oncology, Department of Internal Medicine, Trakya University School of Medicine, 22030, Edirne, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hac\u0131o\u011flu", 
        "givenName": "Muhammet Bekir", 
        "id": "sg:person.0732216477.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732216477.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Trakya University", 
          "id": "https://www.grid.ac/institutes/grid.411693.8", 
          "name": [
            "Division of Medical Oncology, Department of Internal Medicine, Trakya University School of Medicine, 22030, Edirne, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Demircan", 
        "givenName": "Naz\u0131m Can", 
        "id": "sg:person.07435500330.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07435500330.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Trakya University", 
          "id": "https://www.grid.ac/institutes/grid.411693.8", 
          "name": [
            "Division of Medical Oncology, Department of Internal Medicine, Trakya University School of Medicine, 22030, Edirne, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "G\u00f6kyer", 
        "givenName": "Ali", 
        "id": "sg:person.012016242417.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012016242417.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Trakya University", 
          "id": "https://www.grid.ac/institutes/grid.411693.8", 
          "name": [
            "Division of Medical Oncology, Department of Internal Medicine, Trakya University School of Medicine, 22030, Edirne, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Uzuno\u011flu", 
        "givenName": "Sernaz", 
        "id": "sg:person.0603514740.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603514740.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Trakya University", 
          "id": "https://www.grid.ac/institutes/grid.411693.8", 
          "name": [
            "Department of Radiology, Trakya University School of Medicine, Edirne, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tun\u00e7bilek", 
        "givenName": "Nermin", 
        "id": "sg:person.0722407032.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722407032.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Trakya University", 
          "id": "https://www.grid.ac/institutes/grid.411693.8", 
          "name": [
            "Division of Medical Oncology, Department of Internal Medicine, Trakya University School of Medicine, 22030, Edirne, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "\u00c7i\u00e7in", 
        "givenName": "\u0130rfan", 
        "id": "sg:person.01034171740.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01034171740.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Trakya University", 
          "id": "https://www.grid.ac/institutes/grid.411693.8", 
          "name": [
            "Division of Medical Oncology, Department of Internal Medicine, Trakya University School of Medicine, 22030, Edirne, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Erdo\u011fan", 
        "givenName": "B\u00fclent", 
        "id": "sg:person.01135174132.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135174132.79"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/bjc.2013.58", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000012185", 
          "https://doi.org/10.1038/bjc.2013.58"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1007/s13539-012-0074-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005950893"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrd4467", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007854399", 
          "https://doi.org/10.1038/nrd4467"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa065044", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007947936"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/wvn.12147", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009056940"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clgc.2012.09.006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017683657"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.juro.2015.08.071", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020031584"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2015.12.030", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022644363"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.295.21.2516", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023194691"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.juro.2016.12.059", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027377065"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.juro.2016.12.059", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027377065"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.juro.2016.12.059", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027377065"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1303989", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030656737"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1139/h08-075", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032172459"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.critrevonc.2016.08.012", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033758646"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.critrevonc.2016.08.012", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033758646"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.02.2574", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035170611"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(20000801)89:3<604::aid-cncr16>3.0.co;2-q", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036795827"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdp605", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039975559"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(12)70241-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040116470"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrd2380", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044070644", 
          "https://doi.org/10.1038/nrd2380"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/mou.0000000000000207", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046331729"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/mou.0000000000000207", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046331729"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-016-3093-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046959637", 
          "https://doi.org/10.1007/s00280-016-3093-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-016-3093-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046959637", 
          "https://doi.org/10.1007/s00280-016-3093-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.eururo.2016.11.020", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048795941"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmc1400731", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051518311"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2013.50.8267", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053397983"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/jm0204183", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055947476"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/jm0204183", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055947476"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1615/critrevoncog.v17.i3.30", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1068132533"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.18553/jmcp.2016.22.8.979", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1068661689"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075221300", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1152/jappl.1998.85.1.115", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083287696"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000484950", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099627593"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000484950", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099627593"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3322/caac.21442", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100164642"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.22034/apjcp.2017.18.11.2977", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100444004"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41419-018-0388-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101368492", 
          "https://doi.org/10.1038/s41419-018-0388-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41419-018-0388-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101368492", 
          "https://doi.org/10.1038/s41419-018-0388-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41419-018-0388-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101368492", 
          "https://doi.org/10.1038/s41419-018-0388-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3390/cancers10040105", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103153589"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.5387/fms.2018-15", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1107790184"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-04", 
    "datePublishedReg": "2019-04-01", 
    "description": "PURPOSE: To evaluate whether sunitinib and pazopanib treatments are associated with change in skeletal muscle area (SMA) and total lean body mass (LBM) as well as to compare their efficacies and safety profiles in patients with metastatic renal cell cancer (mRCC).\nMETHODS: Thirty-six patients treated with a tyrosine kinase inhibitor were included. Eighteen of them received sunitinib and the rest/remaining received pazopanib in the first line of mRCC treatment. Baseline and follow-up computed tomography studies of the patients were performed to measure cross-sectional areas (cm2) of muscle tissues.\nRESULTS: About 69% of patients were male and median age was 60 (49-68)\u00a0years. Median time interval between two CT imagings was 6.1 (3.1-7.7)\u00a0months and it was similar between the two groups (for sunitinib, 4.9 (2.5-6.9)\u00a0months vs for pazopanib, 7.3 (3.2-9.5)\u00a0months, p\u2009=\u20090.16, respectively). Disease control rate was 77.7% in all patients. Of these, 66.6% in sunitinib group was consisted of four partial responses and eight stable diseases. In addition, 88.8% in pazopanib group was consisted of three partial responses and 13 stable diseases. A significant decrease in SMA and LBM was observed after sunitinib therapy, whereas SMA and LBM values of pazopanib group did not change significantly (p\u2009=\u20090.02 and p\u2009=\u20090.70, respectively). No significant differences were observed between patients with sunitinib, and pazopanib group median PFS [11.9 (95% CI 6.1-17.6) vs 8.1\u00a0months (95% CI 7.2-9.1), respectively; p\u2009=\u20090.28] and median OS [28.6 (95% CI 24.3-32.9) vs 25.5\u00a0months (95% CI 18.9-52.7), respectively; p\u2009=\u20090.42]. Dose-limiting toxicities were significantly more frequent in sunitinib group than in pazopanib group (66.7% vs 22.2%, p\u2009=\u20090.02, respectively).\nCONCLUSIONS: Loss of SMA and LBM with sunitinib was more substantial than with pazopanib. Treatment efficacies of both drugs were similar, but dose-limiting toxicity was more frequent in sunitinib group. Loss of SMA had no significant association with prognosis. Further studies are needed to clarify the possible association between SMA and prognosis in mRCC patients who receive sunitinib or pazopanib.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00280-019-03779-5", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "83"
      }
    ], 
    "name": "Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer", 
    "pagination": "735-742", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "f596302b9643df43cd4ea01a770afadcf4e3dd4e53914686281a6441f50e14a5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30680522"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-019-03779-5"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1111653380"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-019-03779-5", 
      "https://app.dimensions.ai/details/publication/pub.1111653380"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T11:22", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000354_0000000354/records_11731_00000002.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs00280-019-03779-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03779-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03779-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03779-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03779-5'


 

This table displays all metadata directly associated to this object as RDF triples.

232 TRIPLES      21 PREDICATES      63 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-019-03779-5 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N93cfe9d1fe8c4e66ac16cf207ec815ce
4 schema:citation sg:pub.10.1007/s00280-016-3093-8
5 sg:pub.10.1038/bjc.2013.58
6 sg:pub.10.1038/nrd2380
7 sg:pub.10.1038/nrd4467
8 sg:pub.10.1038/s41419-018-0388-1
9 https://app.dimensions.ai/details/publication/pub.1075221300
10 https://doi.org/10.1001/jama.295.21.2516
11 https://doi.org/10.1002/1097-0142(20000801)89:3<604::aid-cncr16>3.0.co;2-q
12 https://doi.org/10.1007/s13539-012-0074-6
13 https://doi.org/10.1016/j.clgc.2012.09.006
14 https://doi.org/10.1016/j.critrevonc.2016.08.012
15 https://doi.org/10.1016/j.ejca.2015.12.030
16 https://doi.org/10.1016/j.eururo.2016.11.020
17 https://doi.org/10.1016/j.juro.2015.08.071
18 https://doi.org/10.1016/j.juro.2016.12.059
19 https://doi.org/10.1016/s1470-2045(12)70241-3
20 https://doi.org/10.1021/jm0204183
21 https://doi.org/10.1056/nejmc1400731
22 https://doi.org/10.1056/nejmoa065044
23 https://doi.org/10.1056/nejmoa1303989
24 https://doi.org/10.1093/annonc/mdp605
25 https://doi.org/10.1097/mou.0000000000000207
26 https://doi.org/10.1111/wvn.12147
27 https://doi.org/10.1139/h08-075
28 https://doi.org/10.1152/jappl.1998.85.1.115
29 https://doi.org/10.1159/000484950
30 https://doi.org/10.1200/jco.2005.02.2574
31 https://doi.org/10.1200/jco.2013.50.8267
32 https://doi.org/10.1615/critrevoncog.v17.i3.30
33 https://doi.org/10.18553/jmcp.2016.22.8.979
34 https://doi.org/10.22034/apjcp.2017.18.11.2977
35 https://doi.org/10.3322/caac.21442
36 https://doi.org/10.3390/cancers10040105
37 https://doi.org/10.5387/fms.2018-15
38 schema:datePublished 2019-04
39 schema:datePublishedReg 2019-04-01
40 schema:description PURPOSE: To evaluate whether sunitinib and pazopanib treatments are associated with change in skeletal muscle area (SMA) and total lean body mass (LBM) as well as to compare their efficacies and safety profiles in patients with metastatic renal cell cancer (mRCC). METHODS: Thirty-six patients treated with a tyrosine kinase inhibitor were included. Eighteen of them received sunitinib and the rest/remaining received pazopanib in the first line of mRCC treatment. Baseline and follow-up computed tomography studies of the patients were performed to measure cross-sectional areas (cm2) of muscle tissues. RESULTS: About 69% of patients were male and median age was 60 (49-68) years. Median time interval between two CT imagings was 6.1 (3.1-7.7) months and it was similar between the two groups (for sunitinib, 4.9 (2.5-6.9) months vs for pazopanib, 7.3 (3.2-9.5) months, p = 0.16, respectively). Disease control rate was 77.7% in all patients. Of these, 66.6% in sunitinib group was consisted of four partial responses and eight stable diseases. In addition, 88.8% in pazopanib group was consisted of three partial responses and 13 stable diseases. A significant decrease in SMA and LBM was observed after sunitinib therapy, whereas SMA and LBM values of pazopanib group did not change significantly (p = 0.02 and p = 0.70, respectively). No significant differences were observed between patients with sunitinib, and pazopanib group median PFS [11.9 (95% CI 6.1-17.6) vs 8.1 months (95% CI 7.2-9.1), respectively; p = 0.28] and median OS [28.6 (95% CI 24.3-32.9) vs 25.5 months (95% CI 18.9-52.7), respectively; p = 0.42]. Dose-limiting toxicities were significantly more frequent in sunitinib group than in pazopanib group (66.7% vs 22.2%, p = 0.02, respectively). CONCLUSIONS: Loss of SMA and LBM with sunitinib was more substantial than with pazopanib. Treatment efficacies of both drugs were similar, but dose-limiting toxicity was more frequent in sunitinib group. Loss of SMA had no significant association with prognosis. Further studies are needed to clarify the possible association between SMA and prognosis in mRCC patients who receive sunitinib or pazopanib.
41 schema:genre research_article
42 schema:inLanguage en
43 schema:isAccessibleForFree false
44 schema:isPartOf Na9a7ce264b5c49eba4b672ecf3475da4
45 Nd808e24e33d24fd89c05094f32b98669
46 sg:journal.1088364
47 schema:name Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer
48 schema:pagination 735-742
49 schema:productId N0d1c446ecc2a48cfb5c09090b90853b2
50 N57db5fe84a1e4368960e7157d5e99546
51 Na64c76da45b54d78853b2aa07531e546
52 Nae4b35484f8e40d9aaa2d8adfa6f7106
53 Nbead760db4e34e10b0581b13022a4693
54 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111653380
55 https://doi.org/10.1007/s00280-019-03779-5
56 schema:sdDatePublished 2019-04-11T11:22
57 schema:sdLicense https://scigraph.springernature.com/explorer/license/
58 schema:sdPublisher N0885a6842e57444794d1b0df56e36703
59 schema:url https://link.springer.com/10.1007%2Fs00280-019-03779-5
60 sgo:license sg:explorer/license/
61 sgo:sdDataset articles
62 rdf:type schema:ScholarlyArticle
63 N01fbd9786ce34f7a83d853212063cf66 rdf:first sg:person.01135174132.79
64 rdf:rest rdf:nil
65 N0885a6842e57444794d1b0df56e36703 schema:name Springer Nature - SN SciGraph project
66 rdf:type schema:Organization
67 N0d1c446ecc2a48cfb5c09090b90853b2 schema:name dimensions_id
68 schema:value pub.1111653380
69 rdf:type schema:PropertyValue
70 N146059efaa4f4895ac82d2156db096e3 rdf:first sg:person.0732216477.22
71 rdf:rest Nfb9d7bdea12b4208927434345d332e3b
72 N5034798f8ebb445c973573305fdaae46 rdf:first sg:person.0603514740.84
73 rdf:rest Nf2df0f93a00b46ea97d7e37171db0ba8
74 N57db5fe84a1e4368960e7157d5e99546 schema:name readcube_id
75 schema:value f596302b9643df43cd4ea01a770afadcf4e3dd4e53914686281a6441f50e14a5
76 rdf:type schema:PropertyValue
77 N5d5e36513e1a49f4aeed8486d7c97a80 rdf:first sg:person.012016242417.01
78 rdf:rest N5034798f8ebb445c973573305fdaae46
79 N7ece4ec11bb545048a460a2091d21d96 rdf:first sg:person.01247047601.58
80 rdf:rest N146059efaa4f4895ac82d2156db096e3
81 N93cfe9d1fe8c4e66ac16cf207ec815ce rdf:first sg:person.01152402121.64
82 rdf:rest N7ece4ec11bb545048a460a2091d21d96
83 Na14e390cee5e42ccbd6e999a1a7a9a0d rdf:first sg:person.01034171740.61
84 rdf:rest N01fbd9786ce34f7a83d853212063cf66
85 Na64c76da45b54d78853b2aa07531e546 schema:name doi
86 schema:value 10.1007/s00280-019-03779-5
87 rdf:type schema:PropertyValue
88 Na9a7ce264b5c49eba4b672ecf3475da4 schema:volumeNumber 83
89 rdf:type schema:PublicationVolume
90 Nae4b35484f8e40d9aaa2d8adfa6f7106 schema:name nlm_unique_id
91 schema:value 7806519
92 rdf:type schema:PropertyValue
93 Nbead760db4e34e10b0581b13022a4693 schema:name pubmed_id
94 schema:value 30680522
95 rdf:type schema:PropertyValue
96 Nd808e24e33d24fd89c05094f32b98669 schema:issueNumber 4
97 rdf:type schema:PublicationIssue
98 Nf2df0f93a00b46ea97d7e37171db0ba8 rdf:first sg:person.0722407032.39
99 rdf:rest Na14e390cee5e42ccbd6e999a1a7a9a0d
100 Nfb9d7bdea12b4208927434345d332e3b rdf:first sg:person.07435500330.66
101 rdf:rest N5d5e36513e1a49f4aeed8486d7c97a80
102 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
103 schema:name Medical and Health Sciences
104 rdf:type schema:DefinedTerm
105 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
106 schema:name Clinical Sciences
107 rdf:type schema:DefinedTerm
108 sg:journal.1088364 schema:issn 0344-5704
109 1432-0843
110 schema:name Cancer Chemotherapy and Pharmacology
111 rdf:type schema:Periodical
112 sg:person.01034171740.61 schema:affiliation https://www.grid.ac/institutes/grid.411693.8
113 schema:familyName Çiçin
114 schema:givenName İrfan
115 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01034171740.61
116 rdf:type schema:Person
117 sg:person.01135174132.79 schema:affiliation https://www.grid.ac/institutes/grid.411693.8
118 schema:familyName Erdoğan
119 schema:givenName Bülent
120 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135174132.79
121 rdf:type schema:Person
122 sg:person.01152402121.64 schema:affiliation https://www.grid.ac/institutes/grid.411693.8
123 schema:familyName Köstek
124 schema:givenName Osman
125 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01152402121.64
126 rdf:type schema:Person
127 sg:person.012016242417.01 schema:affiliation https://www.grid.ac/institutes/grid.411693.8
128 schema:familyName Gökyer
129 schema:givenName Ali
130 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012016242417.01
131 rdf:type schema:Person
132 sg:person.01247047601.58 schema:affiliation https://www.grid.ac/institutes/grid.411693.8
133 schema:familyName Yılmaz
134 schema:givenName Erdem
135 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01247047601.58
136 rdf:type schema:Person
137 sg:person.0603514740.84 schema:affiliation https://www.grid.ac/institutes/grid.411693.8
138 schema:familyName Uzunoğlu
139 schema:givenName Sernaz
140 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603514740.84
141 rdf:type schema:Person
142 sg:person.0722407032.39 schema:affiliation https://www.grid.ac/institutes/grid.411693.8
143 schema:familyName Tunçbilek
144 schema:givenName Nermin
145 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722407032.39
146 rdf:type schema:Person
147 sg:person.0732216477.22 schema:affiliation https://www.grid.ac/institutes/grid.411693.8
148 schema:familyName Hacıoğlu
149 schema:givenName Muhammet Bekir
150 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732216477.22
151 rdf:type schema:Person
152 sg:person.07435500330.66 schema:affiliation https://www.grid.ac/institutes/grid.411693.8
153 schema:familyName Demircan
154 schema:givenName Nazım Can
155 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07435500330.66
156 rdf:type schema:Person
157 sg:pub.10.1007/s00280-016-3093-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046959637
158 https://doi.org/10.1007/s00280-016-3093-8
159 rdf:type schema:CreativeWork
160 sg:pub.10.1038/bjc.2013.58 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000012185
161 https://doi.org/10.1038/bjc.2013.58
162 rdf:type schema:CreativeWork
163 sg:pub.10.1038/nrd2380 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044070644
164 https://doi.org/10.1038/nrd2380
165 rdf:type schema:CreativeWork
166 sg:pub.10.1038/nrd4467 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007854399
167 https://doi.org/10.1038/nrd4467
168 rdf:type schema:CreativeWork
169 sg:pub.10.1038/s41419-018-0388-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101368492
170 https://doi.org/10.1038/s41419-018-0388-1
171 rdf:type schema:CreativeWork
172 https://app.dimensions.ai/details/publication/pub.1075221300 schema:CreativeWork
173 https://doi.org/10.1001/jama.295.21.2516 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023194691
174 rdf:type schema:CreativeWork
175 https://doi.org/10.1002/1097-0142(20000801)89:3<604::aid-cncr16>3.0.co;2-q schema:sameAs https://app.dimensions.ai/details/publication/pub.1036795827
176 rdf:type schema:CreativeWork
177 https://doi.org/10.1007/s13539-012-0074-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005950893
178 rdf:type schema:CreativeWork
179 https://doi.org/10.1016/j.clgc.2012.09.006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017683657
180 rdf:type schema:CreativeWork
181 https://doi.org/10.1016/j.critrevonc.2016.08.012 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033758646
182 rdf:type schema:CreativeWork
183 https://doi.org/10.1016/j.ejca.2015.12.030 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022644363
184 rdf:type schema:CreativeWork
185 https://doi.org/10.1016/j.eururo.2016.11.020 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048795941
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1016/j.juro.2015.08.071 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020031584
188 rdf:type schema:CreativeWork
189 https://doi.org/10.1016/j.juro.2016.12.059 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027377065
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1016/s1470-2045(12)70241-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040116470
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1021/jm0204183 schema:sameAs https://app.dimensions.ai/details/publication/pub.1055947476
194 rdf:type schema:CreativeWork
195 https://doi.org/10.1056/nejmc1400731 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051518311
196 rdf:type schema:CreativeWork
197 https://doi.org/10.1056/nejmoa065044 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007947936
198 rdf:type schema:CreativeWork
199 https://doi.org/10.1056/nejmoa1303989 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030656737
200 rdf:type schema:CreativeWork
201 https://doi.org/10.1093/annonc/mdp605 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039975559
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1097/mou.0000000000000207 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046331729
204 rdf:type schema:CreativeWork
205 https://doi.org/10.1111/wvn.12147 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009056940
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1139/h08-075 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032172459
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1152/jappl.1998.85.1.115 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083287696
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1159/000484950 schema:sameAs https://app.dimensions.ai/details/publication/pub.1099627593
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1200/jco.2005.02.2574 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035170611
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1200/jco.2013.50.8267 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053397983
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1615/critrevoncog.v17.i3.30 schema:sameAs https://app.dimensions.ai/details/publication/pub.1068132533
218 rdf:type schema:CreativeWork
219 https://doi.org/10.18553/jmcp.2016.22.8.979 schema:sameAs https://app.dimensions.ai/details/publication/pub.1068661689
220 rdf:type schema:CreativeWork
221 https://doi.org/10.22034/apjcp.2017.18.11.2977 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100444004
222 rdf:type schema:CreativeWork
223 https://doi.org/10.3322/caac.21442 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100164642
224 rdf:type schema:CreativeWork
225 https://doi.org/10.3390/cancers10040105 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103153589
226 rdf:type schema:CreativeWork
227 https://doi.org/10.5387/fms.2018-15 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107790184
228 rdf:type schema:CreativeWork
229 https://www.grid.ac/institutes/grid.411693.8 schema:alternateName Trakya University
230 schema:name Department of Radiology, Trakya University School of Medicine, Edirne, Turkey
231 Division of Medical Oncology, Department of Internal Medicine, Trakya University School of Medicine, 22030, Edirne, Turkey
232 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...